Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD

Brian J. Lipworth (Lead / Corresponding author), Chris R. W. Kuo

Research output: Contribution to journalLetter

Abstract

The pooled post hoc analysis of three randomised controlled trials by Vestbo et al. [1] found that combinations containing inhaled corticosteroid (ICS) significantly reduced non-respiratory-related mortality in chronic obstructive pulmonary disease (COPD) compared to long-acting bronchodilator therapies alone, the difference amounting to −35% (95% CI −57% to −3%). These studies did not adjudicate on cause of death and only followed patients for up to 1 year. In the IMPACT trial, all-cause mortality was 42% lower and cardiovascular attributed deaths were 52% lower when comparing triple therapy to combined long-acting bronchodilators over 1 year [2].
Original languageEnglish
Article number1802420
JournalEuropean Respiratory Journal
Volume53
Issue number2
DOIs
Publication statusPublished - 1 Feb 2019

Fingerprint

Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Adrenal Cortex Hormones
Mortality
Cause of Death
Randomized Controlled Trials
Therapeutics

Cite this

@article{af52285662604ae19fd9d85974349f03,
title = "Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD",
abstract = "The pooled post hoc analysis of three randomised controlled trials by Vestbo et al. [1] found that combinations containing inhaled corticosteroid (ICS) significantly reduced non-respiratory-related mortality in chronic obstructive pulmonary disease (COPD) compared to long-acting bronchodilator therapies alone, the difference amounting to −35{\%} (95{\%} CI −57{\%} to −3{\%}). These studies did not adjudicate on cause of death and only followed patients for up to 1 year. In the IMPACT trial, all-cause mortality was 42{\%} lower and cardiovascular attributed deaths were 52{\%} lower when comparing triple therapy to combined long-acting bronchodilators over 1 year [2].",
author = "Lipworth, {Brian J.} and Kuo, {Chris R. W.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1183/13993003.02420-2018",
language = "English",
volume = "53",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",

}

TY - JOUR

T1 - Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD

AU - Lipworth, Brian J.

AU - Kuo, Chris R. W.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The pooled post hoc analysis of three randomised controlled trials by Vestbo et al. [1] found that combinations containing inhaled corticosteroid (ICS) significantly reduced non-respiratory-related mortality in chronic obstructive pulmonary disease (COPD) compared to long-acting bronchodilator therapies alone, the difference amounting to −35% (95% CI −57% to −3%). These studies did not adjudicate on cause of death and only followed patients for up to 1 year. In the IMPACT trial, all-cause mortality was 42% lower and cardiovascular attributed deaths were 52% lower when comparing triple therapy to combined long-acting bronchodilators over 1 year [2].

AB - The pooled post hoc analysis of three randomised controlled trials by Vestbo et al. [1] found that combinations containing inhaled corticosteroid (ICS) significantly reduced non-respiratory-related mortality in chronic obstructive pulmonary disease (COPD) compared to long-acting bronchodilator therapies alone, the difference amounting to −35% (95% CI −57% to −3%). These studies did not adjudicate on cause of death and only followed patients for up to 1 year. In the IMPACT trial, all-cause mortality was 42% lower and cardiovascular attributed deaths were 52% lower when comparing triple therapy to combined long-acting bronchodilators over 1 year [2].

U2 - 10.1183/13993003.02420-2018

DO - 10.1183/13993003.02420-2018

M3 - Letter

C2 - 30765485

VL - 53

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 2

M1 - 1802420

ER -